Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024-1759, USA.
Psychol Med. 2010 Feb;40(2):239-51. doi: 10.1017/S0033291709006035. Epub 2009 Jun 3.
Painful physical symptoms (PPS) are both common and reduce the likelihood of remission in major depressive disorder (MDD), based upon results of clinical trials in selected populations. Whether PPS significantly contribute to poorer treatment outcome overall in primary or specialty psychiatric care settings remains unclear.
Out-patients (n=2876) with MDD were treated in the first step of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial with citalopram up to 60 mg/day for up to 14 weeks. Presence of painful symptoms, as well as severity of depression, physical illness, and demographic and treatment factors were examined. Time to and overall rates of remission were analysed in relation to the presence of PPS.
Of the participants, 80% complained of PPS. These patients, both in primary and specialty psychiatric settings, had significantly lower remission rates and took longer to remit. Increasing severity of PPS was associated with greater physical illness burden, lower socio-economic status, absence of private insurance and being female, African-American or Hispanic. After adjustment for these factors, patients with PPS no longer had significantly poorer treatment outcomes.
Presence and severity of PPS is an indicator of MDD that may have poorer treatment outcome with an initial selective serotonin reuptake inhibitor. These poorer treatment outcomes are multifactorial, however, and are not explained by the presence and severity of pain per se.
基于对特定人群临床试验的结果,疼痛的躯体症状(PPS)在重度抑郁症(MDD)中既常见又降低缓解的可能性。在初级或专科精神保健环境中,疼痛躯体症状是否显著导致整体治疗结局更差仍不清楚。
在缓解抑郁症的序贯治疗选择(STAR*D)试验的第一步中,对 MDD 门诊患者(n=2876)用西酞普兰治疗,剂量高达 60 mg/天,最多 14 周。检查疼痛症状的存在情况,以及抑郁、躯体疾病的严重程度、人口统计学和治疗因素。根据 PPS 的存在情况分析缓解的时间和总缓解率。
参与者中有 80%报告有 PPS。这些患者,无论是在初级还是专科精神科环境中,缓解率明显较低,缓解时间更长。PPS 的严重程度增加与躯体疾病负担更大、社会经济地位较低、没有私人保险以及女性、非裔美国人或西班牙裔有关。在调整这些因素后,有 PPS 的患者的治疗结局不再显著更差。
PPS 的存在和严重程度是 MDD 的一个指标,用初始选择性 5-羟色胺再摄取抑制剂治疗可能会有更差的治疗结局。然而,这些更差的治疗结局是多因素的,不能仅用疼痛的存在和严重程度来解释。